Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 794 participants.

Also called NCT07168278

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 794 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07168278
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07168278. Randomized; single masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
Acronym
TNK LATE
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Condition
Tenecteplase
Condition
Thrombolysis
Intervention (Drug)
TNK
Intervention (Drug)
Standard medical treatment
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China (class: other)

Record details

Record id
cardio:ct-nct07168278
Content hash
b0dff4de57d9d8ac83692a7705383cbd0bf00130f8b852ac0ef2121504609509